PRMT1 and diffuse large B-cell lymphoma: A completed phase I clinical trial with PRMT1 (GSK3368715) inhibitor was reported to inhibit cancer cell growth in patients with advanced solid tumors and diffuse large B cell lymphoma (DLBCL) [97].